Financial Contrast: FULGENT GENETIC (FLGT) and GenMark Diagnostics (GNMK)
FULGENT GENETIC (NASDAQ: FLGT) and GenMark Diagnostics (NASDAQ:GNMK) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, dividends and profitability.
This is a summary of current ratings and recommmendations for FULGENT GENETIC and GenMark Diagnostics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
FULGENT GENETIC presently has a consensus price target of $8.50, indicating a potential upside of 116.28%. GenMark Diagnostics has a consensus price target of $14.40, indicating a potential upside of 93.29%. Given FULGENT GENETIC’s higher possible upside, equities research analysts clearly believe FULGENT GENETIC is more favorable than GenMark Diagnostics.
Earnings and Valuation
This table compares FULGENT GENETIC and GenMark Diagnostics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|FULGENT GENETIC||$20.81 million||3.35||$2.17 million||($0.38)||-10.34|
|GenMark Diagnostics||$50.59 million||8.05||-$49.93 million||($1.21)||-6.16|
FULGENT GENETIC has higher revenue, but lower earnings than GenMark Diagnostics. FULGENT GENETIC is trading at a lower price-to-earnings ratio than GenMark Diagnostics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
16.8% of FULGENT GENETIC shares are owned by institutional investors. 58.8% of FULGENT GENETIC shares are owned by insiders. Comparatively, 7.5% of GenMark Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This table compares FULGENT GENETIC and GenMark Diagnostics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
FULGENT GENETIC beats GenMark Diagnostics on 8 of the 11 factors compared between the two stocks.
About FULGENT GENETIC
Fulgent Genetics, Inc. is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. As of December 31, 2015, the Company’s test menu includes approximately 18,000 single-gene tests and over 200 pre-established, multi-gene, disease-specific panels that collectively test for approximately 7,500 genetic conditions, including various cancers, cardiovascular diseases and neurological disorders. The Company’s gene probes are specifically engineered to generate genetic data that is optimized for its software, which enables to rapidly incorporate new genes into its test menu, develop new panels of disease-specific tests and customize tests for its customers.
About GenMark Diagnostics
GenMark Diagnostics, Inc. is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology. It offers four Food and Drug Administration (FDA)-cleared diagnostic tests which run on its XT-8 instrument; its Respiratory Viral Panel; its Cystic Fibrosis Genotyping Test; its Warfarin Sensitivity Test, and its Thrombophilia Risk Test. It also offers a Hepatitis C (HCV) genotyping test and associated custom manufactured reagents, as well as a 2C19 Genotyping Test, versions of which are available for use with its XT-8 instrument for research use only (RUO). Its XT-8 and ePlex test cartridges utilize the combination of distinct electrodes and multiple signal probes to detect dozens of target biomarkers from a single sample, thereby enabling highly multiplexed testing.
Receive News & Ratings for FULGENT GENETIC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FULGENT GENETIC and related companies with Analyst Ratings Network's FREE daily email newsletter.